Share price$3.74
1D+0.8%
Sold putSold callAH
Fulcrum Therapeutics, Inc. Common Stock FULC
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T01:47:57.826Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T21:00:04.007520737Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-12T01:47:57.347792+00:00
Fulcrum Therapeutics, Inc. Common Stock options
Puts——
Calls——
Skew——
Implied move——
Tilt——
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 2.73 | 738.2% | 55.7% | |||
| 25Δ | 3.15 | 679.1% | 45.2% | |||
| 30Δ | 3.44 | 604.8% | 38.4% | |||
| 35Δ | 3.74 | 530.6% | 31.7% | |||
| 40Δ | 4.02 | 461.6% | 25.4% | |||
| 45Δ | 4.14 | 427.3% | 22.5% | |||
| 50Δ | 4.27 | 393.0% | 19.6% | |||
| 55Δ | 4.40 | 358.8% | 16.8% | |||
| 60Δ | 4.53 | 324.5% | 13.9% | |||
| 65Δ | 4.65 | 290.3% | 11.0% | |||
| 70Δ | 4.78 | 256.0% | 8.1% | |||
| 75Δ | 4.91 | 221.7% | 5.2% | |||
| 80Δ | ||||||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.73
- IV
- 738.2%
- B/E move
- 55.7%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.15
- IV
- 679.1%
- B/E move
- 45.2%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.44
- IV
- 604.8%
- B/E move
- 38.4%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.74
- IV
- 530.6%
- B/E move
- 31.7%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.02
- IV
- 461.6%
- B/E move
- 25.4%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.14
- IV
- 427.3%
- B/E move
- 22.5%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.27
- IV
- 393.0%
- B/E move
- 19.6%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.40
- IV
- 358.8%
- B/E move
- 16.8%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.53
- IV
- 324.5%
- B/E move
- 13.9%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.65
- IV
- 290.3%
- B/E move
- 11.0%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.78
- IV
- 256.0%
- B/E move
- 8.1%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.91
- IV
- 221.7%
- B/E move
- 5.2%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
Options history
IV · four-Friday blend236.40%
Daily close
20 observations2026-08-24 — 2026-10-30
Table
| Date | IV (%) |
|---|---|
| 210.09% | |
| 226.02% | |
| 206.05% | |
| 232.07% | |
| 247.34% | |
| 255.06% | |
| 286.33% | |
| 281.57% | |
| 354.20% | |
| 212.20% | |
| 211.04% | |
| 218.65% | |
| 223.76% | |
| 270.80% | |
| 234.19% | |
| 225.64% | |
| 207.81% | |
| 213.48% | |
| 222.79% | |
| 236.40% |
Biotechnology
GALT
Galectin Therapeutics Inc., a clinical-stage biopharmaceutical company, is dedicated to the research and development of therapies for fibrotic, cancerous and other diseases. The…
More →GANX
Gain Therapeutics, Inc., a developing biotechnology company, is dedicated to developing a variety of therapies to treat diseases caused by protein misfolding. The company is…
More →GENB
Generate Biomedicines, Inc. is an innovative biotechnology company at the forefront of protein therapeutics development, leveraging advanced genetic engineering and artificial…
More →GERN
Geron Corporation, an advanced stage clinical biopharmaceutical company, focuses on the development and commercialization of therapies for myeloid hematologic neoplasms. The…
More →GHRS
Description unavailable
More →GLUE
Description unavailable
More →